This Article Full Text Full Text (PDF) All Versions of this Article: 41/5/1063    most recent 01.HYP.0000064943.51878.58v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mogensen, C. E. Articles by Thomas, S. M. Search for Related Content PubMed PubMed Citation Articles by Mogensen, C. E. Articles by Thomas, S. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Diabetes Hazardous Substances DB ENALAPRIL MALEATE Related Collections Type 2 diabetes Clinical Studies

(Hypertension. 2003;41:1063.)
© 2003 American Heart Association, Inc.

Scientific Contributions

Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes

Preterax in Albuminuria Regression: PREMIER

Carl Erik Mogensen; Giancarlo Viberti; Serge Halimi; Eberhard Ritz; Luis Ruilope; György Jermendy; Jiri Widimsky; Pinchas Sareli; Jan Taton; Juan Rull; Gürbüz Erdogan; Pieter W. De Leeuw; Arthur Ribeiro; Ramiro Sanchez; Rachid Mechmeche; John Nolan; Jana Sirotiakova; Ahmed Hamani; André Scheen; Bernhard Hess; Anton Luger; Stephen M. Thomas

From Aarhus Komunehospital (C.E.M.), Aarhus, Denmark; Guy’s Hospital, King’s College (G.V., S.M.T.), London, UK; CHU (S.H.), Grenoble, France; Fakultät f.klin. Medizin (E.R.), Heidelberg, Germany; Hospital 12 de Octubre (L.R.), Madrid, Spain; Bajcsy Zsilinsky Korhaz III Belosztaly (G.J.), Budapest, Hungary; IKEM (J.W.), Prague, Czech Republic; University of the Witwatersrand (P.S.), Johannesburg, South Africa; Katredra I Klinika Chorob (J.T.), Warszawa, Poland; Instituto Nacional de la Nutricion (J.R.), Mexico City, Mexico; Ankara Üniversitesi Tip Fakültesi (G.E.), Ankara, Turkey; Academisch Ziekenhuis Maastricht (P.W.D.L), Maastricht, Nederland; Fundaçao Oswaldo Cruz (A.R.), Sao Paulo, Brazil; Instituto de Cardiologia y Cirugia Cardiovascular (R.S.), Buenos Aires, Argentina; Hôpital La Rabta (R.M.), Tunis Jabbart, Tunisia; the Department of Endocrinology (J.N.), Dublin, Ireland; General Hospital (J.S.), Nitra, Slovakia; Hôpital Mohammed V (A.H.), Rabat, Morocco; CHU Sart Tilman (A.S.), Liege, Belgium; Inselspital Bern (B.H.), Bern, Switzerland; and Abt Endokrinologie (A.L.), Wien-Austria.

Correspondence to Carl Erik Mogensen, Medical Department M, Aarhus Komunehospital, Aarhus University Hospital, 8000 Aarhus, Denmark. E-mail carl.erik.mogensen{at}afdm.au.dk

Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on albumin excretion rate (AER) in patients with type 2 diabetes, albuminuria, and hypertension in a 12-month, randomized, double-blind, parallel-group international multicenter study. Four hundred eighty-one patients with type 2 diabetes and hypertension (systolic BP 140 mm Hg, <180 mm Hg, diastolic BP <110 mm Hg) were randomly assigned (age 59±9 years, 77% previously treated for hypertension). Results from 457 patients (intention-to-treat analysis) were available. After a 4-week placebo period, patients with albuminuria >20 and <500 µg/min were randomly assigned to a combination of 2 mg perindopril/0.625 mg indapamide or to 10 mg daily enalapril. After week 12, doses were adjusted on the basis of BP to a maximum of 8 mg perindopril/2.5 mg indapamide or 40 mg enalapril. The main outcome measures were overnight AER and supine BP. Both treatments reduced BP. Perindopril/indapamide treatment resulted in a statistically significant higher fall in both BP (-3.0 [95% CI -5.6, -0.4], P=0.012; systolic BP -1.5 [95% CI -3.0, -0.1] diastolic BP P=0.019) and AER -42% (95% CI -50%, -33%) versus -27% (95% CI -37%, -16%) with enalapril. The greater AER reduction remained significant after adjustment for mean BP. Adverse events were similar in the 2 groups. Thus, first-line treatment with low-dose combination perindopril/indapamide induces a greater decrease in albuminuria than enalapril, partially independent of BP reduction. A BP-independent effect of the combination may increase renal protection.

Key Words: albuminuria • microalbuminuria • hypertension, renal • diabetes mellitus • angiotensin-converting enzyme

This article has been cited by other articles:

				B. E. de Galan, V. Perkovic, T. Ninomiya, A. Pillai, A. Patel, A. Cass, B. Neal, N. Poulter, S. Harrap, C.-E. Mogensen, et al. Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes J. Am. Soc. Nephrol., April 1, 2009; 20(4): 883 - 892. [Abstract] [Full Text] [PDF]

				K. Fox Benefits of perindopril all along the cardiovascular continuum: the level of evidence Eur. Heart J. Suppl., September 1, 2008; 10(suppl_G): G4 - G12. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]

				I Rietveld, A Hofman, H A P Pols, C M van Duijn, S W J Lamberts, and J A M J L Janssen An insulin-like growth factor-I gene polymorphism modifies the risk of microalbuminuria in subjects with an abnormal glucose tolerance. Eur. J. Endocrinol., May 1, 2006; 154(5): 715 - 721. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Diabetic Nephropathy Diabetes Care, March 1, 2005; 28(3): 745 - 751. [Full Text] [PDF]

				M. J. Krimholtz, J. Karalliedde, S. Thomas, R. Bilous, and G. Viberti Targeting Albumin Excretion Rate in the Treatment of the Hypertensive Diabetic Patient with Renal Disease J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S42 - S47. [Abstract] [Full Text] [PDF]